Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases - p. 1 8. Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment - p. 31 9. Chapter Three: Phosphodiesterase inhibitors and lung diseases - p. 55 10. Chapter Four: Prospects for macrolide therapy of asthma and COPD - p. 83 11. Chapter Five: Targeting the renin angiotensin system for respiratory diseases - p. 111 12. Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD - p. 145 13. Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis - p. 179 14. Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing - p. 226 15. Chapter Nine: Senotherapy for lung diseases - p. 249 16. Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD - p. 273
Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases - p. 1 8. Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment - p. 31 9. Chapter Three: Phosphodiesterase inhibitors and lung diseases - p. 55 10. Chapter Four: Prospects for macrolide therapy of asthma and COPD - p. 83 11. Chapter Five: Targeting the renin angiotensin system for respiratory diseases - p. 111 12. Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD - p. 145 13. Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis - p. 179 14. Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing - p. 226 15. Chapter Nine: Senotherapy for lung diseases - p. 249 16. Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD - p. 273
